[Federal Register: December 1, 2006 (Volume 71, Number 231)] [Notices] [Page 69592] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr01de06-110] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 7, 2006, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, NJ 08066, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: ------------------------------------------------------------------------ Drug Schedule ------------------------------------------------------------------------ Tetrahydrocannabinols (7370)............... I Dihydromorphine (9145)..................... I Difenoxin (9168)........................... I Propiram (9649)............................ I Amphetamine (1100)......................... II Methamphetamine (1105)..................... II Methylphenidate (1724)..................... II Codeine (9050)............................. II Dihydrocodeine (9120)...................... II Oxycodone (9143)........................... II Hydromorphone (9150)....................... II Hydrocodone (9193)......................... II Meperidine (9230).......................... II Morphine (9300)............................ II Thebaine (9333)............................ II Oxymorphone (9652)......................... II Alfentanil (9737).......................... II Sufentanil (9740).......................... II Fentanyl (9801)............................ II ------------------------------------------------------------------------ The company plans to manufacture the listed controlled substances in bulk for sale to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301; and must be filed no later than January 30, 2007. Dated: November 21, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-20344 Filed 11-30-06; 8:45 am] BILLING CODE 4410-09-P